1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)

J.W Riess,E Cohen,J Spicer,P.H Shaw,J Rubio Perez,L Medina Rodríguez,M.F Chaney,S O'Neill,A.W Pedersen,D Mcdowell,E Ehrnrooth,P Garrido Lopez

doi:10.1016/j.annonc.2023.09.2177

1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)

J.W Riess, E Cohen + Show 10 more

https://doi.org/10.1016/j.annonc.2023.09.2177

Copy DOI

Journal: Annals of Oncology

Publication Date: Oct 1, 2023

Affiliation: University of California, San Diego, Hospital Universitario Ramón y Cajal

#Squamous Cell Carcinoma Of The Head And Neck #Non-small Cell Lung Cancer + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.